Sign in
ERNA Stock Price, Chart, Stats & News
Ernexa Therapeutics Inc.
Save
1.98M
Market cap
–
Current P/E
–
Forward P/E
ERNA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.32% |
ROA | -241.40% |
ROE | -1261.63% |
D/E | 0.20x |
Interest coverage ratio | -300.58x |
ERNA valuation
P/E | – |
P/S | – |
P/B | 0.66x |
P/CF | -0.23x |
P/FCF | -0.22x |
P/OCF | -0.23x |
PEG | -0.01x |
EV multiple | -0.36x |
About
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer.
Similar securities
Based on sector and market capitalization
Report issue